5 completed, 3 recruiting, 2 active not recruiting, 1 unknown. 3 Phase 3, 2 Not applicable, 2 Phase 1, 2 Phase 4, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 2, Recruiting 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow this condition Literature Review of Neurotransmitter Agents trials Research Report on Neurotransmitter Agents
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) NT 201, NT 201 Placebo - Neuromuscular Agents, Peripheral Nervous System Agents | Phase 3 | Active not recruiting | Merz Aesthetics GmbH | 300 | 2025-10-01 | 2026-09-10 |
| Efficacy of Satisens® in Reducing Emotional Eating Intervention 1: Satisens®, Intervention 2: Placebo - Emotional Eating, Overweight or Obesity | Not applicable | Completed | José Enrique de la Rubia Ortí, Ph | 84 | 2025-09-15 | 2026-06-22 |
| A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States NT 201, NT 201 Placebo - Neuromuscular Agents, Peripheral Nervous System Agents | Phase 3 | Active not recruiting | Merz North America, Inc. | 300 | 2025-08-27 | 2026-09-10 |
| Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg), Placebo - Suicide, Depressive Disorder, Treatment-Resistant | Phase 2 | Recruiting | National Institute of Mental Health (NIMH) | 50 | 2024-11-06 | 2026-10-05 |
| Nebulized Ketamine for the Treatment of Major Depressive Disorder nebulized ketamine, nebulized midazolam - Severe Depression, Moderate Depression | Phase 3 | Recruiting | Theresa Jacob, PhD, MPH | 40 | 2024-10-16 | 2026-04-24 |
| Natural History of Depression, Bipolar Disorder and Suicide Risk Behavioral Symptoms, Suicide | Recruiting | National Institute of Mental Health (NIMH) | 500 | 2024-09-09 | 2026-10-01 | |
| Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression VTS-K - Treatment Resistant Depression, Major Depressive Disorder | Phase 4 | Completed | Theresa Jacob, PhD, MPH | 15 | 2022-12-06 | 2026-04-21 |
| Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 89 | 2021-09-08 | 2024-03-19 |
| Relative Bioavailability of LY03010 Compared to Listed Drug LY03010; paliperidone palmitate, INVEGA SUSTENNA - Schizophrenia, Psychotic Disorders | Phase 1 | Completed | Luye Pharma Group Ltd. | 281 | 2021-01-13 | 2023-04-25 |
| Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome Guanfacine Extended Release, Placebo - Prader-Willi Syndrome, Aggression | Phase 4 | Completed | Maimonides Medical Center | 15 | 2020-12-17 | 2024-08-19 |
| Lidocaine and Magnesium and Ketamine in Gynecological Surgery lidocaine-magnesium infusion, lidocaine-ketamine infusion, lidocaine infusion - Pain, Postoperative, Pain, Acute | Not applicable | Unknown | Aretaieion University Hospital | 90 | 2020-11-14 | 2022-10-27 |
Depression (4) · Behavioral Symptoms (3) · Depressive Disorder, Major (3) · Depressive Disorder, Treatment-Resistant (3) · Mental Disorders (3) · Mood Disorders (3) · Depressive Disorder (2) · Obesity (2) · Psychotic Disorders (2) · Schizophrenia (2) · Self-Injurious Behavior (2) · Suicide (2) · Abnormalities, Multiple (1) · Acute Pain (1) · Aggression (1)
Behavior (6) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Mental Disorders (3) · Behavioral Symptoms (2) · Mood Disorders (2) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Nutritional and Metabolic Diseases (2) · Pathologic Processes (2) · Aberrant Motor Behavior in Dementia (1) · Anxiety Disorders (1) · Bipolar and Related Disorders (1) · Body Weight (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Ketamine (2) · Paliperidone Palmitate (2) · incobotulinumtoxinA (2) · 6-hydroxynorketamine (1) · Aspirin (1) · Guanfacine (1) · Midazolam (1) · Sucrose (1)
Luye Pharma Group Ltd. (2) · National Institute of Mental Health (NIMH) (2) · Theresa Jacob, PhD, MPH (2) · Aretaieion University Hospital (1) · José Enrique de la Rubia Ortí, Ph (1) · Maimonides Medical Center (1) · Merz Aesthetics GmbH (1) · Merz North America, Inc. (1)
United States (8) · Spain (2) · France (1) · Germany (1) · Greece (1) · Poland (1) · Puerto Rico (1)
Rui Li, MD (2) · Theresa Jacob, PhD, MPH (2) · Carlos A Zarate, M.D. (1) · Deepan Singh, MD (1) · Elizabeth D Ballard, Ph.D. (1) · Gonzalo Mariscal Ruiz-Rico (1) · Kassiani Theodoraki, PhD, DESA (1)